



**HAL**  
open science

## Clinical outcomes according to ECG presentations in infarct-related cardiogenic shock in CULPRIT-SHOCK

Michel Zeitouni, Ibrahim Akin, Steffen Desch, Olivier Barthelemy, Delphine Brugier, Jean-Philippe Collet, Suzanne de Waha-Thiele, John Greenwood, Paul Guedeney, Georges Hage, et al.

### ► To cite this version:

Michel Zeitouni, Ibrahim Akin, Steffen Desch, Olivier Barthelemy, Delphine Brugier, et al.. Clinical outcomes according to ECG presentations in infarct-related cardiogenic shock in CULPRIT-SHOCK. Chest, 2020, 10.1016/j.chest.2020.10.089 . hal-03101339

**HAL Id: hal-03101339**

**<https://hal.sorbonne-universite.fr/hal-03101339>**

Submitted on 24 Apr 2023

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

**Total Word count** = 5559

**Title:** Clinical outcomes according to ECG presentations in infarct-related cardiogenic shock in CULPRIT-SHOCK

**Short title:** ECG presentations in cardiogenic shock

Michel Zeitouni<sup>a</sup>, MD; Ibrahim Akin<sup>b</sup>, MD; Steffen Desch<sup>c</sup>, MD; Olivier Barthélémy<sup>a</sup>, MD; Delphine Brugier<sup>a</sup>, PhD; Jean-Philippe Collet<sup>a</sup>, MD, PhD; Suzanne de Waha-Thiele<sup>d</sup>, MD; John P. Greenwood<sup>e</sup>, MD, PhD; Paul Guedeney<sup>a</sup>, MD; Georges Hage<sup>a</sup>, MD; Marie Hauguel-Moreau<sup>a</sup>, MD; Kurt Huber<sup>f</sup>, MD; Mathieu Kerneis<sup>a</sup>, MD; Marko Noc<sup>g</sup>, MD, PhD; Keith G. Oldroyd<sup>h</sup>, MD; Jan J. Piek<sup>i</sup>, MD, PhD; Stéphanie Rouanet<sup>j</sup>, MS; Stefano Savonitto<sup>k</sup>, MD; Pranas Serpytis<sup>l</sup>, MD, PhD; Johanne Silvain<sup>a</sup>, MD, PhD; Janina Stepinska<sup>m</sup>, MD, PhD; Eric Vicaut<sup>n</sup>, MD, PhD; Christiaan JM Vrints<sup>o</sup>, MD, PhD; Stephan Windecker<sup>p</sup>, MD, PhD; Uwe Zeymer<sup>q</sup>, MD; Holger Thiele<sup>c #</sup>, MD; Gilles Montalescot<sup>a\*#</sup>, MD, PhD, for the CULPRIT-SHOCK trial investigators.

#the last two authors should both be considered as senior authors.

- a. Sorbonne Université, ACTION Study Group, INSERM UMRS\_1166, Institut de cardiologie (AP-HP), Paris, France.
- b. First Department of Medicine, Faculty of Medicine, University Medical Centre Mannheim (UMM), University of Heidelberg, Mannheim, Germany.
- c. Heart Center Leipzig at University of Leipzig and Leipzig Heart Institute, Leipzig, Germany.
- d. University Heart Centre Luebeck, Department of Cardiology, Angiology and Intensive Care Medicine, Luebeck, Germany.
- e. Department of Cardiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
- f. 3<sup>rd</sup> Department of Medicine, Cardiology and Intensive Care Medicine, Wilhelminenhospital and Sigmund Freud University, Medical School, Vienna, Austria.
- g. Center for Intensive Internal Medicine, University Medical Center, Ljubljana, Slovenia.
- h. Golden Jubilee National Hospital, Glasgow, UK.
- i. Amsterdam UMC, University of Amsterdam, Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands.
- j. Statistician unit, StatEthic, Levallois-Perret, France.
- k. Cardiovascular Department, Ospedale Manzoni, Lecco, Italy.
- l. Department of Cardiovascular Medicine, Vilnius University; Centre of Cardiology and Angiology, Vilnius University Hospitals Santariskiu Klinikos, Santariskiu str. 2, 08661, Vilnius, Lithuania.
- m. Institute of Cardiology, Warsaw, Poland.
- n. ACTION Study Group, Unité de Recherche Clinique, Hôpital Lariboisière (AP-HP), Paris, France.
- o. Cardiovascular diseases, University of Antwerp, Belgium.

- P. Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Switzerland.
- Q. Heart Centre Ludwigshafen, Department of Cardiology, Germany.

\*Address for Correspondence:

Professor Gilles Montalescot, ACTION Study Group, Institut de Cardiologie, Hôpital Pitié-Salpêtrière, 47-83 bld de l'Hôpital, 75013 Paris, France  
Tel: +33.1.42.16.30.06, Fax: +33.1.42.16.29.31  
Email: gilles.montalescot@aphp.fr  
Twitter: @ActionCoeur.

### **Funding**

The CULPRIT-SHOCK trial was supported by a grant agreement (602202) from the European Union Seventh Framework Program and by the German Heart Research Foundation and the German Cardiac Society.

### **Conflicts of interest**

M. Zeitouni has received research grants from Institut Servier, Federation Française de Cardiologie and lecture fees from BMS/Pfizer.

JP. Collet has received research grants from AstraZeneca, Bayer, Bristol-Myers Squibb, Daiichi-Sankyo, Eli-Lilly, Fédération Française de Cardiologie, Lead-Up, Medtronic, MSD, Sanofi-Aventis, WebMD.

Kurt Huber has received research grants from AstraZeneca and Sanofi as well as lecture fees from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, Sanofi and the Medicines Company

M. Kerneis has received research grants from Fédération Française de Cardiologie and Institut Servier, consulting fees from Sanofi and Servier.

KG. Oldroyd has received speaker and/or consultancy fees from Abbott Vascular, Boston Scientific, Biosensors and MedAlliance.

JJ. Piek has received fee as consultant for Philips/Volcano

S. Savonitto has received research grants (to his Institution) from Eli-Lilly, Daiichi Sankyo, Novartis; speaker or advisory board fees from Bayer, Astra-Zeneca and Abbott.

J. Silvain has received research grants from Amed, Amgen, Algorythm, Astra-Zeneca, Bayer, Daiichi-Sankyo, Eli Lilly, Fondation de France, Gilead Science, Iroko Cardio, Sanofi-Aventis and Saint-Jude Medical.

J. Stepinska has received research grants, from Bayer, Sanofi; consulting or lecture fees from, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Novartis, Pfizer, Sanofi, Servier

E. Vicaut reports receiving personal fees from Eli Lilly; consultancy from Pfizer, Sanofi, LFB, Abbott, Fresenius, Medtronic, Hexacath; member of data safety monitoring board for CERC, lecture fees from Novartis, and grants from Boehringer and Sanofi

S. Windecker has received research and educational grants from Abbott, Amgen, Bayer, BMS, CSL Behring, Boston Scientific, Biotronik, Edwards Lifesciences, Medtronic, Polares and Sinomed.

U. Zeymer has received research grants or consulting fees from, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, Ferrer, Idorsia, Medicines Company, Medtronic, MSD, Pfizer, Quantum Genomics, Sanofi, Servier, WebMD.

G. Montalescot has received research grants or consulting fees from Abbott, Amgen, Actelion, American College of Cardiology Foundation, AstraZeneca, Axis-Santé, Bayer, Boston-Scientific, Boehringer Ingelheim, Bristol-Myers Squibb, Beth Israel Deaconess Medical, Brigham Women's Hospital, China heart House, Daiichi-Sankyo, Idorsia, Elsevier, Europa, Fédération Française de Cardiologie, ICAN, Lead-Up, Medtronic, Menarini, MSD, Novo-Nordisk, Partners, Pfizer, Quantum Genomics, Sanofi, Servier, WebMD.

I. Akin, O. Barthélémy, D. Brugier, S. de Waha-Thiele, JP. Greenwood, P. Guedeney, G. Hage, M. Hauguel-Moreau, M. Noc, S. Rouanet, S. Desch, P. Serpytis, CJM. Vrints and H. Thiele report no relationships that could be construed as a conflict of interest.

## ABSTRACT

**Background:** The impact of ECG presentations of acute myocardial infarction (AMI) in cardiogenic shock is unknown.

**Research question:** In myocardial infarction with cardiogenic shock, is there a difference in the outcomes and effect of revascularization strategies between non-ST-segment elevation myocardial infarction (NSTEMI) and left bundle branch block (LBBB-MI) versus STEMI?

**Methods:** Cardiogenic shock patients from the CULPRIT-SHOCK trial presenting with NSTEMI or LBBB-MI were compared with STEMI patients for 30-day and 1-year all-cause mortality. The interaction between ECG presentation and the effect of revascularization strategies on outcomes was evaluated.

**Results:** Of 665 cardiogenic shock patients analyzed, 55.9% presented with STEMI, 29.3% with NSTEMI and 14.7% with LBBB-MI. Patients differed in age (68.0 years in STEMI, 71.0 years in NSTEMI and 73.5 years in LBBB-MI,  $p=0.015$ ), cardiovascular risk factors and angiographic severity. There was no difference in the 30-day risk of death between NSTEMI and STEMI (48.7 % vs. 43.0%, aOR 1.05, 95%CI, 0.66 - 1.67,  $p=0.85$ ), nor between LBBB-MI and STEMI (59.2% vs. 43.0%, aOR 1.31, 95%CI 0.73 - 2.34,  $p=0.36$ ). While the univariate risk of 1-year death was higher in NSTEMI and LBBB-MI patients compared with STEMI, ECG presentation was not an independent risk factor of mortality after adjustment (NSTEMI vs. STEMI : 56.4 % vs 46.8 % aOR 1.21, 95%CI 0.76 - 1.92,  $p=0.42$  ; LBBB-MI vs. STEMI : 69.4% vs. 46.8% : aOR : 1.59, 95%CI 0.89 – 2.84,  $p=0.12$ ) . ECG presentation did not modify the effect of the revascularization strategy on 30-day and 1-year mortality ( $p$  interaction =0.91 and 0.97).

**Interpretation:** In patients with cardiogenic shock, NSTEMI and LBBB-MI presentations reflect higher risk profiles than STEMI but are not independent risk factors of mortality. ECG presentations did not modify the treatment effect, supporting culprit-lesion-only PCI as the preferred strategy across the AMI spectrum.

**KEYWORDS:** cardiogenic shock; STEMI; NSTEMI; left bundle branch block; percutaneous coronary intervention.

## INTRODUCTION

Cardiogenic shock is the most frequent cause of mortality in patients admitted with acute myocardial infarction (AMI) <sup>1,2</sup>. This life-threatening complication occurs in 3 to 5 % of non-ST-segment myocardial infarction (NSTEMI) patients and in 10 to 13 % of patients presenting with ST-segment elevation myocardial infarction (STEMI) <sup>3,4</sup>. Emergent percutaneous coronary intervention (PCI) is the only proven strategy that improves survival <sup>5-7</sup>. Guidelines recommend an early invasive strategy for patients presenting with acute myocardial infarction (AMI) and hemodynamic instability, regardless of the ECG presentation <sup>8,9</sup>.

Little is known about the profile of cardiogenic shock patients related to NSTEMI or left bundle branch block (LBBB-MI). Because of the difficulty to quickly determine whether a LBBB is *de novo* or pre-existent, it is often considered as an equivalent of STEMI. However, there is a considerable evolution in the appraisal of LBBB-MI patients in clinical practice and recent European Guidelines, as studies have demonstrated their specific characteristics and natural history <sup>10-13</sup>. Whether the 3 ECG presentations of AMI have different outcomes and are associated with a variation in the effects of treatment strategies in cardiogenic shock is unknown<sup>14,15</sup>.

Thus, using the data of the CULPRIT-SHOCK trial, we aimed to compare the characteristics of patients admitted for cardiogenic shock with STEMI, NSTEMI or LBBB-MI as well as their short- and long-term outcomes and the effect of the revascularization strategy.

## **METHODS**

### **Study design and population**

The present post-hoc analysis included all the patients of the CULPRIT-SHOCK (Culprit Lesion Only PCI versus Multivessel PCI in Cardiogenic Shock) trial for whom the ECG presentation was collected. The investigation conforms to the principle's outlined in the Declaration of Helsinki and was approved by ethics committees involved in the CULPRIT-SHOCK trial. The design of the CULPRIT-SHOCK trial as well as the 30-day and 1-year results have previously been published <sup>16-18</sup>. In brief, this multicenter and open-label trial randomized patients with cardiogenic shock related to AMI and multivessel coronary artery disease to a culprit-lesion-only PCI strategy versus an immediate multivessel PCI strategy. The patients assigned to a culprit-lesion-only PCI strategy could be treated with complementary staged PCI. The primary endpoint of 30-day mortality or renal-replacement therapy occurred more often in patients treated with immediate multivessel PCI <sup>16</sup>.

In the present post-hoc analysis, the baseline 12-lead ECG was recorded and analyzed for each patient of the trial, who was then classified as STE-MI, NSTEMI or LBBB-MI. ST-segment elevation was defined by site investigators as a new ST-elevation  $\geq 1$  mm in  $\geq 2$  contiguous leads <sup>19</sup>. LBBB-MI was described as the association of a supraventricular heart rhythm, a QRS duration  $\geq 120$  ms, a QS or rS complex in lead V1 and a R wave in lead V6 <sup>20</sup>. The new or old status of the LBBB was not collected in the trial. Patients with ECG alterations other than ST-segment elevation or LBBB were considered as NSTEMI.

### **Study endpoints**

In the primary analysis, we compared the 30-day and 1-year all-cause death of patients admitted with cardiogenic shock related to NSTEMI or LBBB-MI with those presenting with cardiogenic

shock related to STE-MI (reference group). The secondary outcome included the composite of all-cause death or renal replacement therapy at 30 days. Then, we assessed whether the effect of revascularization strategies on outcomes of cardiogenic shock patients was consistent across the 3 ECG presentation groups.

### **Statistical analysis**

Continuous variables are reported as median and interquartile range [Q1-Q3] and compared using the Kruskal-Wallis test. Categorical variables are reported as numbers and percentages and compared using the Chi-square or Fisher's exact test. Kaplan-Meier curves were also used to show event rates over time with classification according to ECG presentation and compared using the log-rank test. Patients without events were censored at 30 days or 1-year.

NSTE-MI and LBBB-MI patients were respectively compared with patients presenting with STE-MI, which was the reference in this analysis. Univariate logistic regression was performed to assess the association between ECG presentation and outcomes at 30 days or 1 year, as previously published (14, 16). Multivariate logistic regression models were used to evaluate the independent association between ECG presentation and outcomes. In each model, ECG presentation was adjusted on baseline clinical and procedural characteristics (age, sex, body mass index, cardiovascular risk factors, history of MI, history of stroke, PCI, coronary artery bypass graft or peripheral artery disease, kidney dysfunction, arterial lactate level, fibrinolysis before randomization, resuscitation before randomization, femoral access, triple vessel disease, culprit lesion in the left main or left anterior descending artery, chronic total occlusion, stent in culprit lesion, mechanical circulatory support, therapeutic hypothermia, mechanical ventilation, catecholamine therapy, post-PCI Thrombolysis In Myocardial Infarction [TIMI] flow, randomization group) possibly associated with outcomes in univariate analysis ( $p < 0.2$ ) (**e-table**



**1).** The results are interpreted in terms of adjusted odd ratios (aOR) with their associated 95% confidence interval (CI).

The interaction between ECG presentation and revascularization strategy (randomization group) was evaluated for each outcome using logistic regression. A p-value <0.05 was considered significant. All statistical analyses were performed with SAS release 9.4 (SAS Institute Inc, Cary, NC) statistical software package.

## **RESULTS**

### **Characteristics of STE-MI, NSTEMI and LBBB-MI patients with cardiogenic shock**

A description of the ECG presentation was available for 665 patients (96.9%) of the 686 cardiogenic shock patients related to AMI with multivessel coronary artery disease of the CULPRIT-SHOCK trial. There were 372 cardiogenic shock patients presenting with STE-MI (55.9%), 195 with NSTEMI (29.3%) and 98 with LBBB-MI (14.7%). Patient characteristics were worse in patients with NSTEMI and LBBB, as compared with those with STEMI, with regard to age (68.0 years in STE-MI, 71.0 years in NSTEMI and 73.5 years in LBBB-MI,  $p=0.015$ ), diabetes (25.1 % in STE-MI, 37.7 % in NSTEMI and 50 % in LBBB-MI,  $p<0.001$ ) and most of the cardiovascular risk factors and co-morbidities presented in **Table 1**.

Treatments and results of coronary angiograms according to ECG presentation are displayed in **Table 2**. The degree of severity of coronary artery disease also varied according to the ECG presentation, with triple vessel disease and chronic total occlusion being more frequent in LBBB-MI and NSTEMI patients. The differences in the risk profile at admission are displayed in **Figure 1**.

### **Risk of short-term outcomes according to ECG presentation**

The univariate and adjusted risk of 30-day all-cause death according to ECG presentation is presented in **Table 3 and figure 2**. There was no difference in the univariate and adjusted risk of mortality at 30 days between NSTEMI and STEMI patients (48.7% vs. 43.0%, aOR = 1.05, 95%CI [0.66 - 1.67], p=0.85). Cardiogenic shock patients presenting with LBBB-MI had higher univariate risk of 30-day mortality than STEMI, without significant difference after adjustment on confounding covariates (59.2 % vs. 43.0 %, aOR = 1.31, 95 %CI [0.73 – 2.34], p=0.36). There was no difference in the adjusted risk of all-cause death or renal-replacement therapy when NSTEMI or LBBB were respectively compared with STEMI.

### **Risk of long-term outcome according to ECG presentation**

At 1 year, both NSTEMI and LBBB-MI patients had a higher univariate risk of mortality compared with STEMI (**Table 3 and figure 2**). After adjustment for confounding covariates, NSTEMI was not associated with a different risk of mortality at 1 year as compared with STEMI (56.4% vs. 46.8%, aOR = 1.21, 95%CI [0.76 – 1.34], p=0.42), nor was LBBB-MI (69.4% vs. 46.8%, aOR = 1.59, 95%CI [0.89 – 2.84], p=0.12).

### **Effect of revascularization strategy STEMI, NSTEMI and LBBB patients**

The effect of culprit-lesion-only PCI versus immediate multivessel PCI on all-cause death or renal therapy replacement at 30 days (p interaction = 0.76), all-cause death at 30 days (p interaction = 0.91) and 1-year (p interaction =0.97) was consistent across ECG presentations (**Figure 3**).

## **DISCUSSION**

This post-hoc analysis of the CULPRIT-SHOCK trial analyzed the differences in risk profile and outcomes of patients admitted with STEMI, NSTEMI and LBBB-MI complicated by cardiogenic shock and multivessel coronary artery disease. ECG presentations reflect different

risk profiles, with an ascending proportion of co-morbidities and severity of coronary artery disease from STE-MI to NSTEMI and LBBB-MI <sup>21</sup> . Because of important differences in age and vascular severity, ECG presentations are associated with different shock evolutions with LBBB-MI patients suffering of the highest rate of mortality. The adjusted risk of mortality of NSTEMI and LBBB-MI was not different to STE-MI patients, highlighting the contribution of each respective risk profile rather than the type of ECG presentation itself. The effect of revascularization strategies is consistent across groups supporting that an immediate culprit-lesion-only PCI should be the preferred strategy irrespectively of the initial ECG presentation.

The high risk profile of NSTEMI patients with older age, more risk factors and pre-existent heart disease than STE-MI patients was previously described in nationwide non-shock myocardial infarction registries <sup>22,23</sup> . These differences underlie alternative physio-pathological pathways leading to myocardial oxygen deprivation, ischemia and cardiogenic shock <sup>14</sup> . Whereas, in general, STE-MI results from an acute and complete thrombotic coronary occlusion, NSTEMIs are the consequence of a more insidious and extensive atherosclerotic process involving transient unstable coronary stenosis and microcirculation dysfunction, though often with a persistent epicardial coronary blood flow<sup>24</sup> . As a result, the event of cardiogenic shock in NSTEMI patients is less frequent, as compared with STEMI, and mostly results from more extensive coronary artery disease and prior MIs, in addition to more frequent and more severe co-morbidities <sup>4</sup> .

Little is known about the characteristics of cardiogenic shock patients with AMI and LBBB. While these patients are historically considered and treated as ST-segment elevation presenters, recent findings have demonstrated that LBBB-MI patients are in fact more complex and heterogeneous, with more co-morbidities and less favorable outcomes than STE-MI presenters

<sup>10-12</sup>. Although anterior MI can cause a new LBBB, presuming of *de novo* or pre-existing status of the LBBB is challenging – especially in the setting of cardiogenic shock. In our population, LBBB may more likely be a pre-existent marker of established chronic ischemic heart disease with left ventricular dysfunction and remodeling. This is well illustrated by the high rate of triple-vessel disease and chronic total occlusion.

The difference in mortality rates between groups is modest at 30 days but more important at 1-year. STE-MI, NSTEMI and LBBB-MI patients share a similar short-term high-risk period, involving hemodynamic instability or ventricular arrhythmia leading to cardiac arrest or deadly complications like cardiac rupture or acute mitral insufficiency. Beyond 30 days, STE-MI survivors have a low rate of incident death (+3.8%). In contrast, mortality kept in increasing between 30 days and 1 year in NSTEMI (+7.7%) and LBBB-MI patients (+10.2 %). Overall, patients with LBBB-MI had worst clinical presentations at the acute phase, with more frequent resuscitation before randomization and more severe signs of shock. The very-high risk presentation of patient with LBBB-MI, on top of pre-existent co-morbidities is the major contribution of the worst short-term and long-term outcomes. This was also observed with a lower degree in patients with shock and NSTEMI.

The effect of culprit-lesion-only PCI versus immediate multivessel PCI is consistent across each type of ECG presentation. Thus, as demonstrated by the results of the CULPRIT-SHOCK trial, an immediate culprit-lesion-only PCI strategy should be favored in patients with cardiogenic shock related to AMI and multivessel disease, irrespective of the ECG presentation. This is an important message for daily practice and revascularization decisions in these patients with multiple coronary stenoses potentially accessible to multivessel PCI. While facing the challenge of identifying the culprit lesion in NSTEMI or LBBB-MI patients, interventional cardiologists

should still favor an immediate culprit-lesion-only PCI strategy with staged complementary revascularization to avoid harmful peri-procedural complications and worse outcomes with immediate multivessel PCI.

## **LIMITATIONS**

We acknowledge several limitations for this substudy of the CULPRIT-SHOCK trial. First, this is a post-hoc analysis from a randomized trial and should be interpreted accordingly. Of note, our results are concordant with previous findings concerning LBBB-MI and NSTEMI without cardiogenic shock <sup>25</sup>. Secondly, ECG modifications were solely evaluated by site investigators without further review or adjudication. Thus, no specific criteria such as the modified Sgarbossa criteria could be applied for LBBB. Thirdly, the LBBB status – de novo or pre-existent – was unknown and concerned a low proportion of patients.

## **CONCLUSIONS**

In patients with AMI and cardiogenic shock, NSTEMI and LBBB-MI presentations reflect higher risk profiles contributing to worse evolutions but are not an independent risk factor of mortality. Importantly, there is no evidence of heterogeneity in the effect of revascularization strategies between cardiogenic patients presenting with STE-MI, NSTEMI or LBBB-MI. Our results support culprit-lesion-only PCI as the standard immediate strategy irrespectively of the ECG presentation in AMI complicated by cardiogenic shock.

## **ACKNOWLEDGMENTS**

The first author (M.Zeitouni) and the senior authors (G.Montalescot and H.Thiele) designed the study, gathered, analyzed the data, and drafted the manuscript. A lead statistician (S. Rouanet) and a senior statistician (E.Vicaut) provided an independent statistical analysis, results and

revision. The other authors contributed to data gathering, biological measurements, and critical revision of the manuscript. All the authors vouch for the data and analyses reported.

## REFERENCES

1. Hollenberg SM, Kavinsky CJ, Parrillo JE. Cardiogenic shock. *Ann Intern Med* 1999;131(1):47–59.
2. Granger Christopher B., Bates Eric R., Jollis James G., et al. Improving Care of STEMI in the United States 2008 to 2012. *J Am Heart Assoc* 2019;8(1):e008096.
3. Holmes DR, Berger PB, Hochman JS, et al. Cardiogenic shock in patients with acute ischemic syndromes with and without ST-segment elevation. *Circulation* 1999;100(20):2067–2073.
4. Anderson Monique L., Peterson Eric D., Peng S. Andrew, et al. Differences in the Profile, Treatment, and Prognosis of Patients With Cardiogenic Shock by Myocardial Infarction Classification. *Circ Cardiovasc Qual Outcomes* 2013;6(6):708–715.
5. Berger PB, Tuttle RH, Holmes DR, et al. One-year survival among patients with acute myocardial infarction complicated by cardiogenic shock, and its relation to early revascularization: results from the GUSTO-I trial. *Circulation* 1999;99(7):873–878.
6. Webb JG, Sanborn TA, Sleeper LA, et al. Percutaneous coronary intervention for cardiogenic shock in the SHOCK Trial Registry. *Am Heart J* 2001;141(6):964–970.
7. Hochman JS, Sleeper LA, Webb JG, et al. Early Revascularization in Acute Myocardial Infarction Complicated by Cardiogenic Shock. *N Engl J Med* 1999;341(9):625–634.
8. Roffi M, Patrono C, Collet J-P, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). *Eur Heart J* 2016;37(3):267–315.
9. Amsterdam Ezra A., Wenger Nanette K., Brindis Ralph G., et al. 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes. *Circulation* 2014;130(25):e344–e426.
10. Chang AM, Shofer FS, Tabas JA, Magid DJ, McCusker CM, Hollander JE. Lack of association between left bundle-branch block and acute myocardial infarction in symptomatic ED patients. *Am J Emerg Med* 2009;27(8):916–921.
11. Neeland IJ, Kontos MC, Lemos JA de. Evolving considerations in the management of patients with left bundle branch block and suspected myocardial infarction. *J Am Coll Cardiol* 2012;60(2):96–105.
12. Wong C-K, French JK, Aylward PEG, et al. Patients with prolonged ischemic chest pain and presumed-new left bundle branch block have heterogeneous outcomes depending on the presence of ST-segment changes. *J Am Coll Cardiol* 2005;46(1):29–38.

13. Collet J-P, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevationThe Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). *Eur Heart J* [Internet] [cited 2020 Sep 15];Available from: <https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehaa575/5898842>
14. Jacobs AK, French JK, Col J, et al. Cardiogenic shock with non-ST-segment elevation myocardial infarction: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded coronaries for Cardiogenic shock? *J Am Coll Cardiol* 2000;36(3 Suppl A):1091–1096.
15. Kolte Dhaval, Khara Sahil, Aronow Wilbert S., et al. Trends in Incidence, Management, and Outcomes of Cardiogenic Shock Complicating ST-Elevation Myocardial Infarction in the United States. *J Am Heart Assoc* 3(1):e000590.
16. Thiele H, Akin I, Sandri M, et al. PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock. *N Engl J Med* 2017;377(25):2419–2432.
17. Thiele H, Desch S, Piek JJ, et al. Multivessel versus culprit lesion only percutaneous revascularization plus potential staged revascularization in patients with acute myocardial infarction complicated by cardiogenic shock: Design and rationale of CULPRIT-SHOCK trial. *Am Heart J* 2016;172:160–169.
18. Thiele H, Akin I, Sandri M, et al. One-Year Outcomes after PCI Strategies in Cardiogenic Shock. *N Engl J Med* 2018;379(18):1699–1710.
19. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). *Eur Heart J* 2019;40(3):237–269.
20. Sgarbossa EB, Pinski SL, Barbagelata A, et al. Electrocardiographic diagnosis of evolving acute myocardial infarction in the presence of left bundle-branch block. GUSTO-1 (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) Investigators. *N Engl J Med* 1996;334(8):481–487.
21. Savonitto S, Ardissino D, Granger CB, et al. Prognostic Value of the Admission Electrocardiogram in Acute Coronary Syndromes. *JAMA* 1999;281(8):707–713.
22. Zeymer U, Vogt A, Zahn R, et al. Predictors of in-hospital mortality in 1333 patients with acute myocardial infarction complicated by cardiogenic shock treated with primary percutaneous coronary intervention (PCI); Results of the primary PCI registry of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte (ALKK). *Eur Heart J* 2004;25(4):322–328.
23. Polonski L, Gasior M, Gierlotka M, et al. A comparison of ST elevation versus non-ST elevation myocardial infarction outcomes in a large registry database: Are non-ST myocardial infarctions associated with worse long-term prognoses? *Int J Cardiol* 2011;152(1):70–77.



24. Zeitouni Michel, Barthélémy Olivier, Hauguel-Moreau Marie, et al. Investigator Versus Core Laboratory Evaluation of Coronary Flow and Related Mortality in the CULPRIT-SHOCK Trial. *Circ Cardiovasc Interv* 2019;12(10):e008296.
25. Bansilal S, Aneja A, Mathew V, et al. Long-Term Cardiovascular Outcomes In Patients With Angina Pectoris Presenting With Bundle Branch Block. *Am J Cardiol* 2011;107(11):1565–1570.

## TABLES

**Table 1.** Presentations in STE-MI, NSTEMI and LBBB-MI patients of the CULPRIT-SHOCK trial.

	<b>Total (N=665)</b>	<b>STE-MI (N=372)</b>	<b>NSTEMI (N=195)</b>	<b>LBBB-MI (n=98)</b>	<b>p- value</b>
Age (years), median [IQR]	70.0 [60.0 - 78.0]	68.0 [58.0 - 77.0]	71.0 [63.0 - 78.0]	73.5 [63.0 - 79.0]	0.02
Female	156/664 (23.5%)	90/371 (24.3%)	39/195 (20.0%)	27/98 (27.6%)	0.31
BMI (kg/m <sup>2</sup> )					0.74
N	642	359	190	93	
Median [IQR]	26.8 [24.5 - 29.4]	26.5 [24.6 - 29.4]	27.3 [24.2 - 29.4]	26.8 [24.7 - 29.4]	
<b>Medical history</b>					
Current smoking	173/644 (26.9%)	109/358 (30.4%)	43/190 (22.6%)	21/96 (21.9%)	0.07
Hypertension	391/655 (59.7%)	203/367 (55.3%)	124/192 (64.6%)	64/96 (66.7%)	0.03
Hypercholesterolemia	218/652 (33.4%)	116/365 (31.8%)	68/191 (35.6%)	34/96 (35.4%)	0.60
Diabetes mellitus	212/654 (32.4%)	92/367 (25.1%)	72/191 (37.7%)	48/96 (50.0%)	<0.01
Family history of CAD	77/637 (12.1%)	51/354 (14.4%)	18/188 (9.6%)	8/95 (8.4%)	0.13
Known renal insufficiency	42/657 (6.4%)	19/368 (5.2%)	15/194 (7.7%)	8/95 (8.4%)	0.34
Previous myocardial infarction	107/655 (16.3%)	51/366 (13.9%)	30/193 (15.5%)	26/96 (27.1%)	0.01
Previous stroke	47/658 (7.1%)	22/368 (6.0%)	15/193 (7.8%)	10/97 (10.3%)	0.31
Known peripheral artery disease	76/659 (11.5%)	38/368 (10.3%)	24/194 (12.4%)	14/97 (14.4%)	0.48
Previous PCI	121/655 (18.5%)	54/366 (14.8%)	41/193 (21.2%)	26/96 (27.1%)	0.01

Previous coronary artery bypass grafting	33/659 (5.0%)	8/369 (2.2%)	18/194 (9.3%)	7/96 (7.3%)	<0.01
<b>Group of randomization</b>					<b>0.82</b>
Culprit-lesion-only PCI	335/665 (50.4%)	185/372 (49.7%)	98/195 (50.3%)	52/98 (53.1%)	
Immediate multivessel PCI	330/665 (49.6%)	187/372 (50.3%)	97/195 (49.7%)	46/98 (46.9%)	
<b>Presentation</b>					
Mean blood pressure (mmHg)					0.26
N	569	322	168	79	
Median, [IQR]	75.7 [63.3 - 93.3]	73.3 [63.0 - 91.7]	78.0 [64.2 - 96.7]	73.3 [63.3 - 92.0]	
Heart rate (beats/min)					0.01
N	662	370	194	98	
Median, [IQR]	91.0 [73.0 -108.0]	89.0 [70.0 - 105.0]	97.0 [78.0 - 110.0]	91.5 [75.0 - 109.0]	
Altered mental status	444/662 (67.1%)	238/369 (64.5%)	128/195 (65.6%)	78/98 (79.6%)	0.02
Cold clammy skin and limbs	456/657 (69.4%)	258/366 (70.5%)	127/193 (65.8%)	71/98 (72.4%)	0.40
Oliguria	169/647 (26.1%)	103/359 (28.7%)	38/193 (19.7%)	28/95 (29.5%)	0.05
Arterial lactate > 2 mmol/L	430/647 (66.5%)	225/360 (62.5%)	131/193 (67.9%)	74/94 (78.7%)	0.01
pH<7.36	391/648 (60.3%)	208/361 (57.6%)	111/192 (57.8%)	72/95 (75.8%)	<0.01
Resuscitation before randomization	351/663 (52.9%)	182/370 (49.2%)	110/195 (56.4%)	59/98 (60.2%)	0.08
Atrial fibrillation	90/665 (13.5%)	39/372 (10.5%)	35/195 (17.9%)	16/98 (16.3%)	0.03
Sinus Rhythm	501/665 (75.3%)	288/372 (77.4%)	142/195 (72.8%)	71/98 (72.4%)	0.37
AV-block III	23/665 (3.5%)	17/372 (4.6%)	5/195 (2.6%)	1/98 (1.0%)	0.21
Other rhythm	75/665 (11.3%)	42/372 (11.3%)	17/195 (8.7%)	16/98 (16.3%)	0.15

Left ventricular ejection fraction (%)					<0.01
N	248	132	72	44	
Median, [IQR]	30.0 [25.0 - 40.0]	30.0 [25.0 - 44.0]	37.0 [25.0 - 41.0]	26.5 [20.0 - 32.0]	

STEMI stands for ST-segment elevation myocardial infarction, NSTEMI for non-ST segment elevation myocardial infarction, LBBB for left bundle branch block, IQR for interquartile range, BMI for body mass index, CAD for coronary artery disease, PCI for percutaneous coronary intervention

**Table 2.** Treatments and angiographic findings in STEMI, NSTEMI and LBBB patients of the CULPRIT-SHOCK trial.

	<b>Total</b> (N=665)	<b>STEMI</b> (N=372)	<b>NSTEMI</b> (N=195)	<b>LBBB-MI</b> (n=98)	<b>p-value</b>
<b>Therapeutic strategies</b>					
Mild hypothermia	217/664 (32.7%)	113/372 (30.4%)	70/194 (36.1%)	34/98 (34.7%)	0.35
Fibrinolysis <24 hr before randomization	30/663 (4.5%)	20/370 (5.4%)	5/195 (2.6%)	5/98 (5.1%)	0.28
Mechanical ventilation	536/662 (81.0%)	284/370 (76.8%)	168/195 (86.2%)	84/97 (86.6%)	<0.01
Mechanical circulatory support	185/665 (27.8%)	101/372 (27.2%)	50/195 (25.6%)	34/98 (34.7%)	0.24
<b>Number of vessels with disease</b>					
Triple vessel disease	423/664 (63.7%)	219/371 (59.0%)	138/195 (70.8%)	66/98 (67.3%)	0.02
<b>Vessel related to the infarction*</b>					
Right coronary artery	177/648 (27.3%)	108/367 (29.4%)	51/186 (27.4%)	18/95 (18.9%)	
Left main	58/648 (9.0%)	22/367 (6.0%)	25/186 (13.4%)	11/95 (11.6%)	
Left anterior descending	268/648 (41.4%)	156/367 (42.5%)	69/186 (37.1%)	43/95 (45.3%)	
Left circumflex	138/648 (21.3%)	79/367 (21.5%)	38/186 (20.4%)	21/95 (22.1%)	
Bypass graft	7/648 (1.1%)	2/367 (0.5%)	3/186 (1.6%)	2/95 (2.1%)	
At least 1 chronic total occlusion*	153/648 (23.6%)	72/367 (19.6%)	55/186 (29.6%)	26/95 (27.4%)	0.02
<b>Number of stents in culprit lesion</b>					0.32
No stent	35/664 (5.3%)	15/371 (4.0%)	11/195 (5.6%)	9/98 (9.2%)	
1 stent	323/664 (48.6%)	190/371 (51.2%)	92/195 (47.2%)	41/98 (41.8%)	
2 stents	182/664 (27.4%)	95/371 (25.6%)	59/195 (30.3%)	28/98 (28.6%)	
3 stents or more	124/664 (18.7%)	71/371 (19.1%)	33/195 (16.9%)	20/98 (20.4%)	
Drug eluting stent	592/629 (94.1%)	333/356 (93.5%)	175/184 (95.1%)	84/89 (94.4%)	0.76
Aspiration thrombectomy of culprit lesion	98/664 (14.8%)	72/371 (19.4%)	12/195 (6.2%)	14/98 (14.3%)	<0.01
<b>Antithrombotic therapy administered in the catheterization laboratory</b>					

Aspirin	491/664 (73.9%)	282/372 (75.8%)	131/194 (67.5%)	78/98 (79.6%)	0.04
Clopidogrel	125/664 (18.8%)	69/372 (18.5%)	44/194 (22.7%)	12/98 (12.2%)	0.10
Prasugrel	87/664 (13.1%)	60/372 (16.1%)	15/194 (7.7%)	12/98 (12.2%)	0.02
Ticagrelor	154/664 (23.2%)	92/372 (24.7%)	38/194 (19.6%)	24/98 (24.5%)	0.37
Glycoprotein IIb/IIIa inhibitor	144/664 (21.7%)	99/372 (26.6%)	27/194 (13.9%)	18/98 (18.4%)	<0.01
Cangrelor	18/664 (2.7%)	9/372 (2.4%)	2/194 (1.0%)	7/98 (7.1%)	0.02
Unfractionated heparin	545/664 (82.1%)	301/372 (80.9%)	162/194 (83.5%)	82/98 (83.7%)	0.68
Low-molecular-weight heparin	94/664 (14.2%)	58/372 (15.6%)	25/194 (12.9%)	11/98 (11.2%)	0.45
Bivalirudin	39/664 (5.9%)	24/372 (6.5%)	9/194 (4.6%)	6/98 (6.1%)	0.68
<b>TIMI Flow grade before PCI*</b>					<0.01
TIMI flow grade 0-1-2	434/644 (67.4%)	286/364 (78.6%)	95/185 (51.4%)	53/95 (55.8%)	
TIMI flow grade 3	210/644 (32.6%)	78/364 (21.4%)	90/185 (48.6%)	42/95 (44.2%)	
<b>TIMI Flow grade after PCI*</b>					0.01
TIMI flow grade 0-1-2	136/622 (21.9%)	91/357 (25.5%)	24/174 (13.8%)	21/91 (23.1%)	
TIMI flow grade 3	486/622 (78.1%)	266/357 (74.5%)	150/174 (86.2%)	70/91 (76.9%)	
<b>Catecholamine therapy</b>					
Yes	593/662 (89.6%)	325/370 (87.8%)	177/195 (90.8%)	91/97 (93.8%)	0.19
Duration in (days)					
n	589	321	177	91	
Median, [IQR]	2 [1.0 - 5.0]	2 [1.0 - 4.0]	2 [1.0 - 5.0]	2 [1.0 - 5.0]	0.27
<b>Duration of intensive care (days)</b>					0.04
N	622	346	186	90	
Median, [IQR]	5 [2.0 - 11.0]	4.5 [2.0 - 10.0]	6.0 [2.0 - 14.0]	7 [2.0 - 14.0]	

\* Core Laboratory data.

STE-MI stands for ST-segment elevation myocardial infarction, NSTEMI for non-ST segment elevation myocardial infarction, LBBB-MI for left bundle branch block with myocardial infarction, PCI for percutaneous coronary intervention, TIMI for Thrombolysis In Myocardial Infarction, hr for hour.

**Table 3.** Outcomes according to ECG presentation

Clinical Outcomes	STE-MI (N=372)	NSTE- MI (N=195)	LBBB- MI (n=98)	NSTE-MI vs. STE-MI				LBBB-MI vs. STE-MI			
				Crude OR [95% CI]	P- valu e	Adjusted OR* [95% CI]	p -value	Crude OR [95% CI]	p-value	Adjusted OR* [95% CI]	p - value
<b>30-day</b>											
All-cause death	160 (43.0%)	95 (48.7%)	58 (59.2%)	1.26 [0.89 – 1.78]	0.19	1.05 [0.66 - 1.67]	0.85	1.92 [1.22 – 3.02]	0.01	1.31 [0.73-2.34]	0.36
All-cause death or renal-replacement therapy	176 (47.3%)	99 (50.8%)	60 (61.2%)	1.15 [0.81 – 1.62]	0.43	0.84 [0.53-1.34]	0.47	1.76 [1.12 – 2.77]	0.02	1.05 [0.59-1.88]	0.86
<b>1-year</b>											
<b>All-cause death</b>	174 (46.8%)	110 (56.4%)	68 (69.4%)	1.47 [1.04 – 2.09]	0.03	1.21 [0.76 - 1.92]	0.42	2.58 [1.60 – 4.15]	<0.01	1.59 [0.89-2.84]	0.12

N= 575 patients were included in the multivariate model for 30-day all cause death and 30-day all cause death or renal-replacement therapy. N=592 patients were included in the multivariate model for all-cause mortality. Covariates of adjustment of both models are detailed in e-table 1. STE-MI stands for ST-segment elevation myocardial infarction, NSTE-MI for non-ST segment elevation myocardial infarction, LBBB-MI for left bundle branch block with myocardial infarction.

## **FIGURES**

**Figure 1.** Risk profile of cardiogenic shock patients according to ECG presentation.


**Figure 2.** All-cause mortality at 30 days and 1 year according to ECG presentation. OR stands for Odds Ratio.

**Figure 3.** Effect of revascularization strategy on outcomes according to ECG presentation




### Age (years)

p=0.02




### Resuscitation before admission

p=0.08




### Diabetes

p < 0.01




### Arterial lactate level > 2 mmol/L

p=0.01




### Left main stem lesion


p < 0.01



### Duration of intensive care unit (days)


p=0.04





No at Risk


	0	5	10	15	20	25	30
LBBB-MI	98	59	52	46	43	41	40
NSTEMI	195	138	127	110	104	100	100
STEMI	372	252	229	221	215	213	212



No. at Risk

	0	60	120	180	240	300	360
LBBB-MI	98	38	35	34	30	30	30
NSTEMI	195	97	96	92	89	87	79

### 30-day all-cause mortality according to ECG presentation



### 1-year all-cause mortality according to ECG presentation

